0001415889-24-013612.txt : 20240517 0001415889-24-013612.hdr.sgml : 20240517 20240517180145 ACCESSION NUMBER: 0001415889-24-013612 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240515 FILED AS OF DATE: 20240517 DATE AS OF CHANGE: 20240517 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Winningham Rick E CENTRAL INDEX KEY: 0001302443 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36033 FILM NUMBER: 24961768 MAIL ADDRESS: STREET 1: 901 GATEWAY BOULEVARD CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Theravance Biopharma, Inc. CENTRAL INDEX KEY: 0001583107 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 BUSINESS PHONE: 650-808-6000 MAIL ADDRESS: STREET 1: UGLAND HOUSE, SOUTH CHURCH STREET CITY: GEORGE TOWN, GRAND CAYMAN STATE: E9 ZIP: KY1-1104 4 1 form4-05172024_100519.xml X0508 4 2024-05-15 0001583107 Theravance Biopharma, Inc. TBPH 0001302443 Winningham Rick E C/O THERAVANCE BIOPHARMA US, INC. 901 GATEWAY BOULEVARD SOUTH SAN FRANCISCO CA 94080 true true false false CHIEF EXECUTIVE OFFICER 0 Ordinary Shares 2024-05-15 4 A 0 2068 9.85 A 1852641 D Ordinary Shares 3900 I As Custodian Ordinary Shares 92567 I By Trust Reflects an acquisition from the Issuer pursuant to a restricted share purchase agreement under the Issuer's Amended and Restated 2013 Equity Incentive Plan at a per-share price equal to the closing per-share price of the Issuer's ordinary shares on the Nasdaq Global Market on May 15, 2024. Transaction was with the Issuer and did not involve an open market transaction. /s/ Brett A. Grimaud, Attorney-in-Fact 2024-05-17